H.C. Wainwright lowered the firm’s price target on Cardiff Oncology (CRDF) to $10 from $18 and keeps a Buy rating on the shares following the Q2 report. The firm reduced its probability of approval for onvansertib to 25% from 40%, seeing a higher risk profile following the most recent data.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDF:
- Largest borrow rate increases among liquid names
- Promising Outlook for Cardiff Oncology’s Onvansertib Despite Phase II Trial Challenges
- Cardiff Oncology Reports Q2 2025 Financial Results
- Closing Bell Movers: Qorvo, Starbucks jump after quarterly reports
- Cardiff Oncology announces data from CRDF-004 trial